Top

International Journal of Clinical Oncology

Published in:

01-01-2019 | Review Article

Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

Authors: Katsuyuki Hotta, Kiichiro Ninomiya, Eiki Ichihara, Katsuyuki Kiura

Published in: International Journal of Clinical Oncology | Issue 1/2019

Abstract

The significance of evaluating oncogenes, including EGFR mutations, ALK abnormalities, and PD-L1 expression has become broadly recognized with recent advances in molecular biology. It is now extremely important to investigate tumor oncogene status in each patient at the initial diagnosis. By contrast, the significance of conducting a re-biopsy in the salvage setting has not been systematically reviewed. This review reports that the significance of a re-biopsy varies depending on the clinical situation.

Hotta K, Matsuo K, Ueoka H et al (2004) Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:3852–3859CrossRefPubMed

Hotta K, Matsuo K, Ueoka H et al (2004) Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 15:1782–1789CrossRefPubMed

Hotta K, Matsuo K (2007) Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2:96CrossRefPubMed

Hotta K, Fujiwara Y, Matsuo K et al (2007) Recent improvement in the survival of patients with advanced non small cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer 109:939–948CrossRefPubMed

Hotta K, Takigawa N, Hisamoto-Sato A et al (2013) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol 43:1115–1123CrossRefPubMed

Ninomiya K, Hotta K, Hisamoto-Sato A et al (2016) Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. Int J Clin Oncol 21:81–87CrossRefPubMed

Hotta K, Ninomiya K, Takigawa N et al (2015) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain. Jpn J Clin Oncol 45:603–604PubMed

Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefPubMed

Kris MG, Johnson BE, Berry LD et al (2014) Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 311:1998–2006CrossRefPubMedPubMedCentral

10.

Hotta K, Kiura K, Toyooka S et al (2007) Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small-cell lung cancer. J Thorac Oncol 2:632–637CrossRefPubMed

11.

Mok TS, Wu Y-L, Ahn M-J et al (2017) AURA3 Investigators. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376:629–640CrossRefPubMed

12.

Jänne PA, Yang JC, Kim DW et al (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689–1699CrossRefPubMed

13.

Hata A, Katakami N, Yoshioka H et al (2015) Spatiotemporal T790M Heterogeneity in individual patients with EGFR-mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI. J Thorac Oncol 10:1553–1559CrossRefPubMed

14.

Ichihara E, Hotta K, Kubo T et al (2018) Clinical significance of repeat rebiopsy in detecting the EGFR T790M secondary mutation in patients with non-small cell lung cancer. Oncotarget 9(50):29525–29531CrossRefPubMedPubMedCentral

15.

Hata A, Masago K, Katakami N et al (2014) Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer. J Thorac Oncol 9:e64–e65CrossRefPubMed

16.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T et al (2018) FLAURA Investigators. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125CrossRefPubMed

17.

National Comprehensive Cancer Network homepage. https://www.nccn.org/. Accessed 5 May 2018

18.

Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68:7–30CrossRefPubMed

19.

Tokaca N, Wotherspoon A, Nicholson AG et al (2017) Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. Lung Cancer 111:65–68CrossRefPubMed

20.

Peters S, Camidge DR, Shaw AT et al (2017) ALEX Trial Investigators. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829–838CrossRefPubMed

21.

Hida T, Nokihara H, Kondo M et al (2017) Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet 390:29–39CrossRefPubMed

22.

Horinouchi H, Maemondo M, Hida T et al (2017) Phase 2 study of ceritinib in patients with ALK + NSCLC with prior alectinib treatment in Japan: ASCEND-9. J Thorac Oncol 12(Supple 2):S1952–S1953CrossRef

23.

Isozaki H, Hotta K, Ichihara E et al (2016) Protocol design for the bench to bed trial in alectinib-refractory non-small-cell lung cancer patients harboring the EML4-ALK fusion gene (ALRIGHT/OLCSG1405). Clin Lung Cancer 17:602–605CrossRefPubMed

24.

Gainor JF, Dardaei L, Yoda S et al (2016) Molecular mechanisms of resistance to first- and second-Generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6:1118–1133CrossRefPubMedPubMedCentral

25.

Reck M, Rodríguez-Abreu D, Robinson AG et al (2016) KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375:1823–1833CrossRefPubMed

26.

Sheng J, Fang W, Yu J et al (2016) Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer. Sci Rep 6:20090CrossRefPubMedPubMedCentral

27.

Song Z, Yu X, Zhang Y (2016) Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. Lung Cancer 99:166–171CrossRefPubMed

28.

Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265CrossRefPubMed

29.

Gadgeel S, Kowanetz F, Zou W et al Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L + NSCLC: Results from the randomized OAK study. ESMO 2017 (Abs 1296O)

30.

Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550CrossRefPubMed

31.

Gandhi L, Rodriguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378(22):2078–2092CrossRefPubMed

32.

Kato Y, Hotta K, Takigawa N et al (2014) Factor associated with failure to administer subsequent treatment after progression in the first-line chemotherapy in EGFR-mutant non-small cell lung cancer: Okayama Lung Cancer Study Group experience. Cancer Chemother Pharmacol 73:943–950CrossRefPubMed

33.

Hotta K, Kiura K, Tabata M et al (2014) A Survey of Japanese thoracic oncologists’perception of diagnostic and treatment strategies for EGFR-mutant or EML4-ALK-fusion non-small cell lung cancer. Chest 146:e222–e225CrossRefPubMed

34.

Hotta K, Tabata M, Kiura K et al (2007) Gefitinib induces premature senescence in non-small-cell lung cancer cells with or without EGFR gene mutation. Oncol Rep 17:313–317PubMed

35.

Gainor JF, Shaw AT, Sequist LV et al (2016) EGFR Mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res 22:4585–4593CrossRefPubMedPubMedCentral

36.

Kim TJ, Hong SA, Kim O et al (2017) Changes in PD-L1 expression according to tumor infiltrating lymphocytes of acquired EGFR-TKI resistant EGFR-mutant non-small-cell lung cancer. Oncotarget 8:107630–107639PubMedPubMedCentral

37.

Kowanetz M, Socinski MA, Zou W et al (2018) IMpower150: Efficacy of atezolizumab plus bevacizumab and chemotherapy in 1L metastatic nonsquamous NSCLC across key subgroups. Presented at: 2018 AACR Annual Meeting, 2018; Chicago, Illinois. Abstract CT076

38.

Haratani K, Hayashi H, Tanaka T et al (2017) Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Ann Oncol 28:1532–1539CrossRefPubMed

Title: Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice
Authors: Katsuyuki Hotta
Kiichiro Ninomiya
Eiki Ichihara
Katsuyuki Kiura
Publication date: 01-01-2019
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 1/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1344-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma

Fertility preservation for female cancer patients

Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer

Does tumour effraction during robotic partial nephrectomy have any impact on recurrence?

Preoperative predictors of difficult hypopharyngeal exposure by retractor for transoral robotic surgery

Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer